文献速递神经肌肉病

碳水化合物、脂质及载脂蛋白代谢血液标志物与肌萎缩侧索硬化风险:瑞典AMORIS队列超过20年随访

Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort.
PubMed 文献 · Ann Neurol · 2017-01-01

基于瑞典AMORIS队列636,132名1985-1996年入组并随访至2011年的成人,评估血清葡萄糖、总胆固醇、甘油三酯、载脂蛋白B(apoB)和A-I(apoA-I)等标志物与肌萎缩侧索硬化(ALS)发病的关联。Cox模型显示LDL-C、apoB及apoB/apoA-I比值升高与ALS发病率增高相关,高血糖(≥6.11mmol/L)与发病率降低相关;诊断前10年ALS患者LDL-C、HDL-C、apoB、apoA-I渐升而LDL-C/HDL-C与apoB/apoA-I比值渐降。

要点

  • LDL-C、apoB及apoB/apoA-I比值升高与ALS发病风险增加相关。
  • 高血糖(≥6.11mmol/L)与ALS发病率降低相关。
  • ALS诊断前10年已出现脂质和载脂蛋白代谢标志物动态改变。

核心结论

  • 碳水化合物、脂质和载脂蛋白代谢的改变与ALS风险相关,并可能作为诊断前数十年的前驱表现。
  • apoB与apoA-I之间以及LDL-C与HDL-C之间的失衡可能是ALS的病因机制,需进一步研究。

研究设计与样本

  • 基于瑞典AMORIS队列,1985-1996年纳入636,132名男性和女性,测量血清葡萄糖、总胆固醇、甘油三酯、apoB和apoA-I,LDL-C和HDL-C直接测量或计算。
  • 队列随访至2011年底,使用Cox模型和混合效应模型分析标志物与ALS发病的关联及诊断前20年的变化。

主要发现

  • LDL-C每增加一个单位,ALS发病风险HR=1.14(95%CI 1.02-1.27)。
  • apoB每增加一个单位,ALS发病风险HR=1.68(95%CI 1.17-2.42)。
  • apoB/apoA-I比值每增加一个单位,ALS发病风险HR=1.90(95%CI 1.29-2.78)。
  • 高血糖水平(≥6.11mmol/L)与ALS发病率降低相关,HR=0.62(95%CI 0.42-0.93)。
  • 高LDL-C/HDL-C比值(≥3.50)与ALS发病率增高相关,HR=1.50(95%CI 1.15-1.96);高apoB/apoA-I比值(男性≥0.90,女性≥0.8)HR=1.41(95%CI 1.04-1.90)。

关键数值与推荐

  • LDL-C每增加一个单位与ALS发病率正相关(HR=1.14,95%CI 1.02-1.27)。
  • apoB每增加一个单位与ALS发病率正相关(HR=1.68,95%CI 1.17-2.42)。
  • apoB/apoA-I比值每增加一个单位与ALS发病率正相关(HR=1.90,95%CI 1.29-2.78)。
  • 高血糖(≥6.11mmol/L)与ALS发病率负相关(HR=0.62,95%CI 0.42-0.93)。
  • 高LDL-C/HDL-C比值(≥3.50)HR=1.50(95%CI 1.15-1.96);高apoB/apoA-I比值(男性≥0.90,女性≥0.8)HR=1.41(95%CI 1.04-1.90)。

临床怎么用

  • 对于脂质和载脂蛋白代谢异常者,尤其是apoB/apoA-I或LDL-C/HDL-C比值升高者,应关注ALS相关神经系统症状。
  • 血糖水平与ALS风险的关联需结合临床背景解读,不应据此改变糖尿病管理。
  • 血液代谢标志物的动态变化可能有助于识别ALS前驱期,但目前尚不能作为独立诊断工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the associations of blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms with the future risk of amyotrophic lateral sclerosis (ALS). METHODS: In the Apolipoprotein-related MOrtality RISk study, we enrolled 636,132 men and women during 1985-1996 in Stockholm, Sweden, with measurements of serum glucose, total cholesterol, triglycerides, apolipoprotein B (apoB), and apolipoprotein A-I (apoA-I). Serum low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were either directly measured or calculated from total cholesterol, triglycerides, and apoA-I. The cohort was followed until the end of 2011. We used Cox models and mixed-effects models to, first, estimate the associations between these biomarkers and ALS incidence and, second, to assess the changes of these biomarkers during the 20 years before ALS diagnosis. RESULTS: One-unit increase of LDL-C (hazard ratio [HR] = 1.14; 95% confidence interval [CI] = 1.02-1.27), apoB (HR = 1.68; 95% CI = 1.17-2.42), and apoB/apoA-I ratio (HR = 1.90; 95% CI = 1.29-2.78) was associated with a higher incidence of ALS. High glucose level (≥6.11mmol/L) was associated with a lower incidence (HR = 0.62; 95% CI = 0.42-0.93), whereas high LDL-C/HDL-C (≥3.50; HR = 1.50; 95% CI = 1.15-1.96) and high apoB/apoA-I (≥0.90 for men, ≥0.8 for women; HR = 1.41; 95% CI = 1.04-1.90) ratios were associated with a higher incidence. During the 10 years before diagnosis, ALS patients had increasing levels of LDL-C, HDL-C, apoB, and apoA-I, whereas gradually decreasing levels of LDL-C/HDL-C and apoB/apoA-I ratios. INTERPRETATION: Alterations in the carbohydrate, lipid, and apolipoprotein metabolisms are associated with ALS risk and may serve as prodromal symptoms decades before ALS diagnosis. The imbalance between apoB and apoA-I as well as between LDL-C and HDL-C may be an etiological mechanism for ALS and needs to be further studied. Ann Neurol 2017;81:718-728.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Mariosa D, Hammar N, Malmström H, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol. 2017. PMID: 28437840. doi:10.1002/ana.24936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。